Aseptic challenges: the experts' view - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Aseptic challenges: the experts' view
Leading pharmaceutical experts talk to Pharmaceutical Technology Europe about trends and challenges in aseptic techniques and technologies.


Pharmaceutical Technology Europe
Volume 21, Issue 12

What have been the key innovations that have shaped current aseptic practices and techniques?


Jerold Martin
Henderson: The number one consideration for aseptic practices and technique is risk minimization. Since the mid-1990s, the development of isolators and restricted access barrier systems (RABS) has substantially changed how operators interact with sterile drug product and their associated technique. A physical barrier between the operator and the critical zone of the isolator controlled at positive pressure with HEPAfiltered air creates a high level of contamination control. Most interactions through isolators and RABS are done through glove ports, which again limits the risk to the associated product. In addition, the ability to biodecontaminate the critical zone and clean-in-place/steam-in-place (CIP/SIP) contact parts has led to less operator involvement and further reduces risk. Magriotis: Isolation technology is replacing conventional clean room aseptic technology within the most developed areas of the pharmaceutical industry. The technology's major benefit is the higher aseptic conditions that can be achieved and maintained during manufacturing. Isolators provide a complete barrier between product and operators, who are the highest source of contamination in aseptic processing. Isolators also guarantee a higher sterility assurance level after decontamination compared with conventional clean room technology (usually 6 Log contaminants reduction versus 3 Log reduction). This is achieved by means of vaporized hydrogen peroxide.


(George Doyle/Getty Images)
Furthermore, in 2008, the European Commission issued a GMP document for sterile drugs preparation stating that the sealing of sterile vials with aluminium caps must happen under Grade A laminar air flow. Consequently, the most innovative machinery manufacturers have reviewed the design of their aluminium capping machines; the latest models incorporate features that make them suitable to work under laminar air flow and that minimize particle generation to maintain the required level of air cleanliness. Martin: Key innovations have been singleuse systems (processscale filter capsules, tubing, biocontainers, etc.), which are presterilized (by gamma irradiation) and preassembled to eliminate aseptic connections and cleaning. These systems have been further enabled by the introduction of sterile connectors. Use of singleuse systems and sterile connectors reduces risk of both microbial contamination and chemical contamination from lottolot or producttoproduct carryover or from cleaning agent residues. Because they are closed systems, they can even enable sterile processing to be done outside of isolators or Class A environments.


David Henderson Jr
Another key innovation is the development of new high capacity 0.1Ám-rated filters with high mycoplasma removal capability. These are used for sterilizing filtration of soy peptonebased bacterial culture media used in aseptic filling line validation to ensure the absence of mycoplasma, such as Acholeplasma laidlawii, in the sterile media fill validation of the aseptic filling line.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology Europe,
Click here